Loading
Cancer costs push patients into debt and make them skip treatment. Asking about money at every visit, and having someone to help, catches this before it does harm.
Financial toxicity affects a large share of patients even in insured and universal systems and is associated with non-adherence and worse survival. Validated instruments (COST-FACIT) exist, and financial navigation programmes have shown reductions in patient debt and distress in US trials. The proposal is to embed a short financial toxicity screen in routine patient-reported outcome collection at each cycle, with an automatic referral to a financial navigator and a data feed to payers documenting the burden by drug and regimen.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares Screening for distress: what the thermometer can and cannot do, Money after treatment: what the cost of cancer does once the treatment has finished, Prices and value.